News Post

Mankind Pharma secures CCI approval for ₹13,360-crore worth acquisition of Bharat Serums and Vaccines | Mint

LivemintLivemint · 3d
Mankind Pharma secures CCI approval for  ₹13,360-crore worth acquisition of Bharat Serums and Vaccines | Mint

- The Competition Commission of India (CCI) has approved the proposed acquisition of Bharat Serums and Vaccines by Mankind Pharma for ₹13,630 crore. - Mankind Pharma announced in July that it would acquire Bharat Serums and Vaccines from private equity firm Advent International for around ₹13,630 crore. - Mankind Pharma will raise up to ₹10,000 crore through the issuance of non-convertible debentures and commercial papers. - The acquisition of Bharat Serums and Vaccines will establish Mankind Pharma as the market leader in the Indian women's health and fertility segment. - Mankind Pharma is one of the largest pharmaceutical companies in India, engaged in developing, manufacturing, and marketing pharmaceutical finished dosage formulations. - Bharat Serums and Vaccines is involved in research, development, manufacturing, and distribution of pharmaceutical formulations, APIs, and health supplements.

Comments

Download the medial app to read full posts, comements and news.